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AbstrAct
Introduction Rett syndrome (RTT) is a pervasive 
neurodevelopmental disorder that presents with 
deficits in brain functioning leading to language and 
learning regression, characteristic hand stereotypies 
and developmental delay. Different mutations in the 
gene implicated in RTT—methyl-CpG-binding protein 
2 (MECP2) establishes RTT as a disorder with divergent 
symptomatology ranging from individuals with severe to 
milder phenotypes. A reliable and single multidimensional 
questionnaire is needed that can embrace all symptoms, 
and the relationships between them, and can map 
clinically meaningful data to symptomatology across the 
lifespan in patients with RTT. As part of the HealthTracker-
based Tailored Rett Intervention and Assessment 
Longitudinal (TRIAL) database, the Rett Evaluation of 
Symptoms and Treatments (REST) Questionnaire will 
be able to marry with the physiological aspects of the 
disease obtained using wearable sensor technology, 
along with genetic and psychosocial data to stratify 
patients. Taken together, the web-based TRIAL database 
will empower clinicians and researchers with the 
confidence to delineate between different aspects of 
disorder symptomatology to streamline care pathways 
for individuals or for those patients entering clinical trials. 
This protocol describes the anticipated development 
of the REST questionnaire and the TRIAL database 
which links with the outcomes of the wearable sensor 
technology, and will serve as a barometer for longitudinal 
patient monitoring in patients with RTT.
Methods and analysis The US Food and Drug 
Administration Guidance for Patient-Reported Outcome 
Measures will be used as a template to inform the 
methodology of the study. It will follow an iterative 
framework that will include item/concept identification, 
item/concept elicitation in parent/carer-mediated focus 
groups, expert clinician feedback, web-based presentation 
of questionnaires, initial scale development, instrument 
refinement and instrument validation.
Ethics and dissemination The study has received 
favourable opinion from the National Health Service (NHS) 
Research Ethics Committee (REC): NHS Research Ethics 
Committee (REC)—London, Bromley Research Ethics 
Committee (reference: 15/LO/1772).
IntroductIon
Rett syndrome (RTT) can trace its genesis 
to a clinical waiting room in Vienna (1965)1 
where Dr Rett first observed the clinical signs 
and symptoms of RTT. Symptoms usually 
appear between 6 and 18 months after birth2 
and clinically RTT presents with impairments 
in brain functioning leading to language and 
learning regression, hand stereotypies (hand 
washing/wringing) and developmental stag-
nation. RTT is predominantly found in young 
females with an incidence of about 1:10000 
live births.3 There are geographical varia-
tions4 with one Australian study indicating a 
prevalence of about 1:90005. The prevalence 
is probably underscored by the high clin-
ical variability of the disease and hence the 
frequency could be underestimated. Loss 
of function in the methyl-CpG-binding protein 
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Protocol
Strengths and limitations of the study
 ► The new Rett Evaluation of Symptoms and 
Treatments (REST) questionnaire will capture 
clinically meaningful change of symptomatology in 
individuals with Rett syndrome across the lifespan.
 ► The HealthTrackerTM-based Tailored Rett 
Intervention and Assessment Longitudinal  (TRIAL) 
database will link the behavioural data with the 
physiological aspects of the disease and has the 
potential to be used globally, allowing for quicker 
development of decision-support analytics and 
personalised care.
 ► The  use of HealthTracker, a multimodal eHealth 
web-based monitoring platform, will make the TRIAL 
database as user friendly as possible and allows it to 
be tailored to the individual participant.
 ► The TRIAL database will enable the streamlining 
of treatment and expedite triaging of care by 
signposting patients to correct specialists sooner to 
enable timely intervention.
 ► Participation might be time consuming for families.
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2 (MECP2) gene is responsible for the disorder in the 
vast majority of cases,6 with rarer cases being attributed 
to mutations in CDKL5 and FOXG1 gene7 8 leading to 
atypical or variant RTT. More recently, mutations in other 
less known candidate genes have emerged such as those 
encoding ankyrin repeat proteins and neuronal acetyl-
choline receptor subunits.9 MeCP2 is a highly conserved 
nuclear protein abundant in the mammalian brain10 and 
notably the disorder is reversible in mice models of RTT.11
MeCP2 acts as a critical epigenetic modulator in the 
mammalian brain, controlling overlapping mecha-
nisms such as DNA methylation and post-translational 
mechanisms.12 Through differential post-translational 
modification at serine 164,13 MeCP2 may help in limiting 
transcriptional noise14 of other genes. For example, 
mutations in the gene switch-insensitive 3 family member 
A (SIN3A), a MECP2 interactor and transcriptional 
repressor—crucial for cortical integrity, causes intellec-
tual disability and autism spectrum disorder (ASD)15 and 
the MECP2R306C mutation prevents MeCP2 from inter-
acting with the NCoR/histone deacetylase 3 (HDAC3) 
complex resulting in impediments in social and cogni-
tive functioning in animal models.16 MeCP2 has complex 
genome level modalities, and the general opinion is that 
loss of the transcriptional repressor function of MECP2 
impacts other genes crucial for postnatal neuronal devel-
opment and has led others to suggest that this leads to 
a suboptimal brain.17 This seems to be the significant 
driver for the classical RTT clinical phenotype. Genes 
in neuronal development tend to be long (100 kb or 
larger)18 and as the transcriptional repression function 
of MECP2 is biased towards longer genes,19 it is likely 
that impairments of long genes associated with neuronal 
development dictates the functional and developmental 
versatility of the MeCP2 protein seen in RTT. This has a 
knock-on effect on the homoeostasis of excitatory and 
inhibitory pathways20 21 in RTT brains leading to the clin-
ical versatility that is commonly observed.
MECP2 being an X-linked gene has an impact on the 
phenotype of patients with RTT and on the clinical 
severity. The X chromosome inactivation can cause uneven 
expression of wild type and mutant alleles resulting in 
skewed patterns of RTT phenotype severity22 23 and the 
degree of DNA methylation-dependent long gene repres-
sion.19 The range of functional ability in patients with 
RTT is, therefore, broad and depending on the type of 
genetic mutation ranges from patients with severe func-
tional impairments to those with milder symptoms24; 
hence assessment and care pathways must be individually 
tailored to each affected person.
Although there have been considerable advances in 
understanding the genetics and into the genetic testing 
of RTT, the diagnosis of RTT is based on the 2010 revised 
consensus clinical criteria3 (see table 1 in Ref. 3) and 
recommends that all individuals with RTT should be 
first be assessed according to the revised clinical criteria 
followed by a thorough genetic test for MECP2. Given that 
about 3%–5% of RTT individuals who fulfil the diagnostic 
clinical criteria do not have MECP2 mutations, and this 
is even higher for atypical RTT cases,25 more recently 
clinical predictors that can facilitate a clinician’s deci-
sion making to order genetic testing for RTT have been 
provided.26 This showed that the likelihood of a having a 
positive MECP2 test was greatest in patients with partial 
or complete attenuation of hand skills. Impairments in 
gait and hand stereotypies were also strong predictors. 
Of interest was that loss of speech did not discriminate 
whether an individual was MECP2+ or MECP2-.
Pre-existing measures in rtt
As far as we are aware, no complete instrument has been 
developed for individuals with RTT that can capture 
longitudinal pharmacological, behavioural, genetic and 
psychosocial information, as well as an ability to correlate 
this with the physiological aspects of the disease. Previous 
datasets/instruments have been inconsistent and provide 
limited information on the behavioural and physiological 
facets of the disease. While some might provide informa-
tion on the genetic diagnoses of individuals with RTT, 
there is a lack of consistency. First, RettBase collected 
mainly molecular genetic data from the Australian 
cohort of patients with RTT.27 Some other instruments 
have included both genetic and clinical data, although 
the clinical data were limited. InterRETT, an Australian 
Rett syndrome database, was based on data collection by 
distributing a questionnaire to families.28 The Italian Rett 
Database and Biobank consisted of 357 patients and had 
20 structured and seven descriptive clinical items along 
with 17 structured genetic items.29 The British Isles Rett 
Syndrome Survey, included 275 British Rett patients and 
had 271 structured and 94 descriptive clinical items, 
and six structured genetic items.30 An American survey 
collected data on the natural history of the disease that 
allowed researchers and physicians to access compre-
hensive patient data on more than 1000 individuals 
with RTT.31 32 These datasets were preserved and inte-
grated into the Rett Networked Database30 and offers an 
amalgamated data repository for researchers to access 
anonymised patient information. Elsewhere, the Japanese 
RTT database includes the clinical data from 102 females 
with a median age of 11 years old.33
Capture of disease severity and sensitivity to change 
throughout the lifespan in patients are important elements 
that need to be considered when developing clinically 
meaningful outcome measures. The Unified Parkinson’s 
Disease Rating Scale is a good example of an outcome 
measure that is effective and can capture disease severity 
and clinically meaningful change of symptoms of Parkin-
son’s disease.34 With rare diseases, the Sanfilippo Behaviour 
Rating Scale, a 68-item questionnaire developed using 
44 families, is also effective and can map the behavioural 
phenotype of children with Sanfilippo syndrome to disease 
progression and/or results from treatment across the 
lifespan.35 In RTT, the current outcome measures are inad-
equate in their ability to capture disease severity across the 
lifespan, although others have made significant headway 
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Figure 1 Flow diagram illustrating the sequence of steps 
showing how data obtained from the TRIAL database can be 
used to provide timely intervention to streamline treatment 
outcomes in patients with RTT syndrome. REST, Rett 
Evaluation of Symptoms and Treatments ; RTT, Rett 
syndrome.
in this area. The 37-item motor–behavioural assessment 
(MBA) incorporates historical items with items from direct 
clinician evaluations and has been used to describe clinical 
severity in RTT,36 37 while the Rett Syndrome Behavioural 
Questionnaire (RSBQ), a validated checklist, was designed 
to differentiate individuals with RTT compared with those 
with severe intellectual disability.38 Other measures tested 
in RTT include the Anxiety Depression and Mood Scale 
(ADAMS),39 the clinician based International Scoring 
System40 41 to evaluate the disease severity, Vineland Adap-
tive Behaviour Scale,42 the 13-item Rett Clinical Severity 
Scale (RCSS)37 43 and its modified version.42 Others have 
developed RTT specific anchors such as for the Clinical 
Global Impression Severity Scale based on scores from the 
RCSS for improved outcome measures in clinical trials.44 
Quality of Life measures such as the Child Health Question-
naire-P50 have also been used in RTT45 including a recent 
phase II open-label clinical trial using glatiramer acetate.46 
Some of these measures such as the MBA, RSBQ, ADAMS 
and RCSS have been implemented into clinical trials 
to evaluate the effect of insulin-like growth factor (IGF-
1)47 or sarizotan48 in individuals with RTT or to develop 
a novel scoring tool (Rett Severity Score (RSS)) to assess 
the impact of IGF-1 treatment in RTT.41 Other scales, such 
as the Mullen Scales for Early Learning used in other rare 
disorders,49 have also been adapted for use in RTT.47 These 
measures are not without their faults. Some have suggested 
that the MBA can be difficult to use with some items that 
describe disease regression having not been validated.24 
This is important given that in some patients with RTT, 
disease regression has been described as transient or often 
goes unrecognised.50 Others such as the RSBQ although 
are suitable to measure some aspects of behaviour such as 
mood and anxiety51 might not be able to capture the salient 
features of behaviour as an outcome measure in a clinical 
trial in patients with RTT. Furthermore, there is differing 
reliability of anxiety scales in RTT, with ADAMS especially 
its Social Avoidance subscale having the best psychometric 
properties in comparison to the RSBQ.52 While no outcome 
measure will be perfect, these studies have paved the way 
for more sensitive outcome measures to be developed such 
as the validated 15-item Gross Motor Scale for individuals 
with RTT.53
Autonomic function in rtt
Large cross-sectional studies investigating the genotype–
phenotype relationships have revealed divergence in the 
phenotype seen in individuals with RTT.54 55 These were 
the first studies of sufficient sample size that bestowed 
important information on the genotype and phenotype 
relationships in RTT, and have been elegantly summarised 
elsewhere.24 Some mutations or variants dictate a more 
severe phenotype when it comes to motor abilities24 54 55 and 
cardiorespiratory phenotypes.24 56 Moreover, at present it is 
unknown whether autonomic dysfunction is governed by 
any specific mutation in RTT.24 56 Assessing the autonomic 
dysfunction in individuals in RTT is therefore a pressing 
clinical concern.
Autonomic dysfunction is a pivotal factor that requires 
consideration when managing patients with rare disorders 
such as RTT. From our clinical experience when managing 
patients in the Centre for Interventional Paediatric Psycho-
pharmacology and Rare Diseases,57 autonomic dysfunction 
is often found in patients who do not respond to treatment 
and those with significant functional disability. Auto-
nomic dysfunction co-occurs in the context of emotional 
and behavioural dysregulation and recently using wear-
able sensor technology, we have shown that Emotional, 
Behavioural and Autonomic Dysregulation (EBAD) is a 
crucial factor that needs to be considered when managing 
patients with RTT.58 59 Although autonomic dysfunction has 
been investigated in individuals with RTT,60–63 the progres-
sion of autonomic dysfunction and the developmental 
trajectory of EBAD has never been researched. Moreover, 
the components of EBAD in a questionnaire that can map 
across other symptomatology longitudinally in individuals 
with RTT has not previously been shown.
AIm
The objective of this study is to develop and validate a 
comprehensive multisystem questionnaire (Rett Evaluation 
of Symptoms and Treatments (REST)) that can profile the 
symptomatology of patients with RTT and is sensitive to 
change across the lifespan allowing better understanding of 
patient needs. In parallel, information collected using wear-
able sensor technology58 59 will be linked to data obtained 
from the REST questionnaire, genetic data and information 
about available psychosocial support from the patient and 
their family, to form a comprehensive Tailored Rett Inter-
vention and Assessment Longitudinal (TRIAL) database. 
The TRIAL database will streamline treatment approaches 
to expedite triaging of care by signposting patients to correct 
specialists earlier than is currently happening (figure 1). 
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Specifically, the functionality of the multimodal Health-
Tracker platform will be exploited so that anonymised data 
from the TRIAL database can be used to develop a parent/
carer alert system to signal when it may be useful to request 
unscheduled clinician appointments. Using this function-
ality, the TRIAL database will also be able to stratify patients 
to inform adaptive clinical trial design, by allowing pre-ex-
isting datasets to be used so that rare disease trials can be 
done in a more cost-effective manner.
methods And AnAlyses
The title of this questionnaire was based on the feedback 
of the focus groups involving parents and carers of chil-
dren with RTT from the parent-based charities such as 
Reverse Rett UK and clinician feedback. It will incorpo-
rate elements from previous scales40 52 and standardised 
RTT questionnaires—data from the Natural History 
Study,3 RSBQ38 and the modified version of the RSS Scale 
(RSSS).42 It is anticipated that the questionnaire will not 
take more than 30 min to complete.
The US Food and Drug Administration Guidance 
for Patient-reported Outcome Measures (PROM)64 will 
be used as a template to guide the methodology in the 
study. It was described in Santosh et al57 65 and will follow 
an iterative framework that will involve item/concept 
identification, item/concept elicitation in parent/carer 
mediated focus groups, clinician feedback, web-based 
presentation of questionnaires, initial scale development, 
instrument refinement and instrument validation.
stage 1: qualitative development of the rest questionnaire
Concept identification
For this initial phase, a systematic literature review will be 
conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses66 to identify signs 
and symptoms that are deemed to be problematic in RTT. A 
draft version will be reviewed by expert clinicians who have 
substantial experience in RTT and ASD. Common themes 
will be identified and draft version of the questionnaire will 
be prepared based on their feedback.
Concept elicitation
This stage will involve parents/carers of individuals aged 
between 6 and 40 years with RTT. A series of focus groups 
anticipated to last about 1.5 hours will be conducted as 
part of the concept elicitation stage. These focus groups 
will include parents/carers of individuals with RTT from 
the parent-based charities, such as Reverse Rett UK, and 
clinicians who see patients with RTT. The groups will 
follow a semistructured format using open-ended ques-
tions to allow participants to discuss their experiences and 
views. Some of the focus groups will be on item genera-
tion while others may centre on reviewing draft versions 
of the questionnaire identifying pertinent themes. Focus 
groups will be audio recorded and each group will 
include approximately 4–6 parents/carers of children 
with RTT. Up to two researchers may be present for the 
focus groups, which will be led by a consultant child and 
adolescent psychiatrist/specialist. All participants will 
also be asked to complete a demographic questionnaire.
Web-based presentation of questionnaires on the HealthTracker 
platform
HealthTracker, a web-based health monitoring platform,67 
has been successfully trialled in multicentric EU FP7 
studies68 69 and in a questionnaire development and vali-
dation study.70 Parents and carers will be shown how the 
REST questionnaire might appear on the HealthTracker 
platform, how the response options to the questionnaire 
could be presented and whether a choice of single or multi-
ple-choice questions would be appropriate. The various 
views of the focus groups will be used to choose the most 
optimal web-based visualisation of the questionnaire.
Tool review
As far as the authors are aware, no questionnaire exists 
that not only is RTT focused but can capture a broad 
range of problematic themes, in particular, the devel-
opmental trajectory of EBAD. Nor do these existing 
questionnaires/scales attempt to marry this with the 
physiological measurements from wearable sensor tech-
nology. At this stage, a further literature review will be 
conducted to identify any themes that may have been 
missed during the focus groups and whether any further 
areas of RTT symptomatology that were not highlighted 
in the focus groups needs to be addressed. In addition, 
parents/carers from Reverse Rett UK will be consulted 
and any feedback incorporated into the tool review stage.
Following the focus groups, study participants will be 
sent a copy of the draft version of the questionnaire (via 
e-mail or post). Once this part has been completed, a 
draft operating beta version of the questionnaire will be 
finalised.
stage 2: validation of the rest questionnaire
This stage of the study will involve parents/carers of 
individuals aged between 6 and 40 years with RTT. 
Questionnaires to assess the longitudinal trajectory 
of symptomatology in rare diseases have proven to be 
difficult to validate.71 72 To broach this conundrum, it is 
important to focus on the symptoms and not just the clin-
ical diagnosis, and be able to evaluate the symptom level 
across other comparable patient groups. At the neuronal 
level, the brains of RTT and ASD patients share many 
core features.73 Both RTT and ASD exhibit behaviours 
that might overlap that is, there are deficits in social 
behaviour and speech and in both cases individuals may 
share common stereotypical behaviours.74 Due to these 
similarities and based on consultation with clinicians with 
expertise in ASD, as a comparator group, this stage of the 
study will also include parents/carers/partners of individ-
uals aged between 6 and 40 years with ASD with significant 
intellectual disability. It will also involve clinicians who 
see patients with RTT and ASD who will test the clini-
cian version of the questionnaire. Participants (parents/
carers and clinicians) will be recruited to complete the 
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respective versions of the REST questionnaire as well as 
other standardised questionnaires—namely the RSSS 
and the RSBQ (table 1). The RSSS37 42 43 75 and the 
RSBQ38 51 have previously been used in studies in patients 
with RTT. Pertinent information will also be taken from 
the RTT Natural History Study.31 32 It is anticipated that 
50 participants in the RTT cohort and 50 in the ASD with 
significant intellectual disability cohort will complete 
the questionnaire battery. Although there is significant 
symptom overlap in patients with RTT and ASD, partic-
ipants in the ASD cohort will be asked to complete only 
the relevant questions in the questionnaire battery that 
would be applicable and relevant to them.
The questionnaire battery will be presented to study 
participants in HealthTracker, a multimodal web-based 
portal for remote online completion using developmen-
tally appropriate interfaces. Participants will be given a 
unique ID number and log-in information and will be 
asked to complete the questionnaires independently. The 
research team will be able to support participants with 
questionnaire completion should they need it. Where 
applicable, participants will also be able to complete 
paper versions of the questionnaires if they request them. 
Participant medical records will be accessed only by 
members of the study team to validate the questionnaire 
against details of diagnoses obtained from patient case 
notes as well as against the Development and Well-Being 
Assessment (DAWBA)76 and treatment/medication status 
if they are available in case notes. Patient records will also 
be used to gain genetic information on the specific muta-
tion and diagnosis. Consent will be obtained to access 
medical notes.
All participants will be asked to complete the question-
naire battery, at baseline, again after 1 week and then 
between 4 and 6 months after first completion to assess 
questionnaire stability.
stage 3: wearable sensor technology
The use of wearable sensor technology to improve treat-
ment outcomes has gathered momentum in recent years77 
and is currently being used to develop new outcome 
measures in patients with complex neurodisability such 
as amyotrophic lateral sclerosis.78 Using wearable sensor 
technology as a PROM is not without its challenges. In 
RTT, wearable technology has been used to explore respi-
ratory and cardiac function in observational studies79 80 
and in two recent clinical trials,46 47 however, inherently 
captured biometric data can be noisy especially from 
quasiperiodic oscillations from cardiac rhythms. Wrist 
worn devices might be particularly susceptible to this 
type of noise. To mitigate these issues, we have applied 
the methods described previously81 82 to analyse heart 
rate variability and electrodermal activity as metrics 
when evaluating wrist sensor biometric data and auto-
nomic function in a 15-year-old girl with RTT. We were 
able to demonstrate a recalibration of the autonomic 
equilibrium from pretreatment to post-treatment using 
buspirone (30 mg/day),58 and subsequent improvement 
in EBAD in this girl. Quasiperiodic oscillations cannot be 
easily quantified using conventional methods. To manage 
this, phase-rectified signal averaging83 may be used in 
conjunction with spectral factorisation and applied to the 
beat-to-beat interval data, which is particularly prone to 
extraneous noise. This methodology coupled with EDA 
assessment will provide more sensitive methods to capture 
changes in autonomic physiology in patients with RTT. In 
the context of this study, the outcomes of the wearable 
sensor technology will marry into the outcomes of the 
newly developed questionnaire (REST), with psychoso-
cial and genetic data to create the TRIAL database. The 
technology will be evaluated in individuals with RTT, ASD 
and healthy controls.
Sample size
Justification for Sample Size
Owing to the small sample population of individuals with 
rare and complex genetic disorders, formal modelling to 
obtain sample size estimates will not be readily applicable.
Stage 1: Questionnaire Development Stage
It is anticipated that the total number of participants for 
the questionnaire development stage of the study will be 
between 10 and 20 (including participants and clinicians). 
In our experience, focus groups involving families with 
children with rare diseases are well versed with the prob-
lems associated with the condition in question. Often, the 
themes that need to be addressed get saturated after a 
couple of focus groups, leading to us getting the basic 
structure of the items needed to be tested in stage 2.
Stage 2: Questionnaire Validation Stage
The total number of participants for the questionnaire 
validation stage of the study will be 150 participants 
(n=100 RTT cohort and n=50 ASD cohort). The number 
in the ASD cohort will be split so that 25 parents/carers 
will either have a male or female diagnosed with ASD.
Stage 3: Wearable Sensor Technologies Stage
The total number of participants for the wearable tech-
nology stage of the study is expected to be 100 participants 
(n=50 RTT cohort and n=50 (25 male and 25 female) ASD 
cohort). This part of the study will also include a matched 
healthy control group.
Stage 4: Longitudinal Monitoring in Patients with RTT
Longitudinal data capture on a 3-monthly basis from 80 to 
100 parents/carers of individuals with RTT will be under-
taken using the REST questionnaire over a 12–18 month 
period. Ethics submission for stage 4 of the study will be 
done after stages 1–3 have been completed.
Recruitment
Information sheets (and age appropriate information 
sheets where relevant) will be provided for all partici-
pants, in addition to consent forms. Information sheets 
will emphasise that participant involvement in the 
research is voluntary and they have the right to withdraw 
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from the research at any time, without giving a reason. 
In addition, participants will be advised that participating 
or withdrawing from the research will have no impact on 
their usual care that they are currently receiving or will 
receive in the future. A minimum of 24 hours will be given 
between providing study information and recruitment of 
participants into the study.
Stage 1: Questionnaire Development Stage Recruitment
Parents/carers of individuals with RTT and clinicians 
who work with individuals with RTT will be recruited. Due 
to the group-based nature of the focus groups, parents/
carers or clinicians who have not provided consent will not 
be able to partake in focus groups and will be excluded. 
The focus groups comprise parents/carers of individuals 
with RTT and clinicians working with patients with RTT. 
Depending on the nature of the focus groups about 4–6 
participants will take part in each focus group.
Questionnaire Development Stage: Inclusion Criteria
 ► Parents/carers/partners/relatives of individuals aged 
between 6 and 40 years with RTT.
 ► Clinicians who work within healthcare settings in 
South London and Maudsley (SLaM) National Health 
Service (NHS) Foundation Trust that see children 
and/or adults with RTT and associated developmental 
conditions.
 ► Without any exclusion for concurrent stable 
medication.
Questionnaire Development Stage: Exclusion Criteria
 ► Parents/carers whom do not have a reasonable level of 
English. This is because a reasonable level of English 
will be required to engage in the focus groups.
Stage 2: questionnaire validation stage recruitment
For this stage of the study, parents/carers of individuals with 
RTT and those with ASD will be recruited via clinician/
researcher invite. Study participants will be under the care 
of a service within SLaM NHS Foundation Trust. Where rele-
vant, parents/carers/partners/relatives of individuals with 
RTT and ASD will be asked to provide details of their clini-
cian at the time of consent so that they can also be contacted 
by the research team and invited to take part.
Questionnaire Validation Stage: Inclusion Criteria
 ► Parents/carers of individuals aged between 6 and 
40 years with RTT or ASD.
Questionnaire Validation Stage:  Exclusion Criteria
 ► If parents/carers of individuals aged between 6 and 
40 years with RTT or ASD are not able to (or expected 
to not be able to) complete questionnaires they will 
be excluded from the study.
 ► Parents/carers who do not have a reasonable level 
of English will be excluded from the validation stage 
of the study. This is because a reasonable level will 
be required to complete questionnaires, which will 
only be available in English at the validation stage. 
A research assistant my assist the parent/carer in 
completion.
Stage 3: wearable sensor technologies stage recruitment
Individuals aged between 6 and 40 years with RTT and 
ASD and parents/carers/partners/relatives of individ-
uals with RTT and ASD will be recruited via clinician/
researcher invite. Information sheets (and age appro-
priate information sheets where relevant) will be 
provided for all participants, in addition to consent forms 
and where applicable assent forms. Healthy controls will 
be recruited via clinician/researcher invite using widely 
used and appropriate advertising channels.
Wearable Sensor Technologies Stage: Inclusion Criteria
RTT
 ► Females aged 6–40 years with confirmed diagnosis of 
RTT (via clinician/researcher invite)
 ► Parents/carers/partners/relatives of individuals aged 
6–40 years with RTT
ASD
 ► Males and females aged 6–40 years with ASD (via 
clinician/researcher invite)
 ► Parents/carers/partners/relatives of individuals aged 
6–40 years with ASD
Healthy controls
 ► Males and females aged 6–40 years considered to be 
healthy for their age (via clinician/researcher invite)
 ► Are capable of understanding and complying with the 
requirements of the protocol
Wearable Sensor Technologies Stage: Exclusion Criteria
RTT
 ► Individuals aged 6–40 years with RTT who are not able 
to (or expected to not be able to) wear the wearable 
sensor technology will be excluded from the study
 ► Parents/carers/partners/relatives of individuals aged 
6–40 years with RTT who do not have a reasonable 
level of English
ASD
 ► Individuals (aged 6–40 years with ASD who are not 
able to (or expected to not be able to) wear the sensor 
technology will be excluded from the study.
 ► Parents/carers/partners/relatives of individuals aged 
6–40 years with ASD who do not have a reasonable 
level of English
Healthy controls
 ► Individuals who are not able to (or expected to not be 
able to) wear the sensor technology will be excluded 
from the study.
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 ► Individuals who do not have a reasonable level of 
English
AnAlyses PlAn
Questionnaire development
Data obtained from the focus groups will be recorded 
securely and transcribed accurately, paying close atten-
tion to the identified themes and issues. The analysis will 
be performed as described previously.65 In brief, the focus 
group data will be organised into clinically meaningful 
themes using thematic and content analysis. Following 
this, to manage the qualitative data generated from the 
focus groups, NVivo software (version 11) will be used 
and the data analysis will be guided by the framework for 
thematic analysis.84
Questionnaire validation
The quantitative data will be analysed using the latest 
version of the SPSS statistical package (version 24).
Internal consistency
Internal consistency of the measures will be reported using 
Cronbach’s alpha. Alpha coefficients ≥0.85 will be indica-
tive of reasonable evidence of internal reliability.85 Where 
applicable, ‘alpha if deleted analyses’ will be performed 
to see if omitting any item(s) from the (subthemes of the) 
questionnaire would strengthen the measure.
Test–retest reliability
Intraclass correlation (ICC) will be used to assess 
test–retest reliability on subscale and total scores as 
described.86 Given the exploratory nature of this study, 
weighted Cohen’s kappa values will also be determined to 
assess test–retest reliability at the item level. The ICC will 
also be performed after 4 to 6 months after initial comple-
tion of the questionnaire to assess the long-term stability 
of the new questionnaire.
Validity
Validity (discriminative power) of the new questionnaire 
will be assessed using Receiver Operating Character-
istic (ROC) analyses as described in Santosh et al.57 65 As 
there are no gold standard questionnaires for patients 
with RTT, where applicable the ROC analyses will also 
be performed on the scores on the RTT Natural History 
Study, the RSBQ and the RSSS. Where necessary and if 
data are available, analysis of variance (ANOVA; general 
linear model) will be performed with grouping variable 
DAWBA diagnoses (coded in 1 for positive and coded 0 
for negative diagnosis) so that the differences in REST 
scoring can be assessed.
Factor analysis
Studies involving small sample sizes have often been 
plagued by the inappropriate use of exploratory factor 
analysis (EFA) or principal component analysis (PCA) to 
identify clinically meaningful factor items.87 Many recom-
mendations have been put forward regarding sample 
sizes but there does not seem to be an overall consensus.88 
Some have suggested improbable sample sizes that would 
not be feasible for studies of rare and complex genetic 
diseases.89 In these instances, methods to reveal the 
multidimensional aspects of factor structure are not as 
straightforward. Recently, the regularised exploratory 
factor analysis (REFA) was introduced90 that is recom-
mended over EFA and PCA, when samples sizes are less 
than 50. Despite this new approach, it is unclear whether 
the REFA would be applicable for a multidimensional 
questionnaire in a condition with many variables. In the 
context of the new questionnaire, the robustness of the 
REST will be evaluated using tools applicable for smaller 
samples sizes90 and those used in exploratory studies as 
described recently91.
Gender differences
In stage 3 (Wearable Sensor Technologies Stage), if the 
data meet the requirements for parametric testing, the 
general linear model (ANOVA) covaried for gender will 
be applied to the RTT and ASD cohorts.
study dAtes
The study is expected to complete by January 2019.
dIssemInAtIon
The goal of this study is to develop and validate a new 
RTT questionnaire. Data from the REST questionnaire 
will be linked with the data from the wearable sensor 
technology as well as psychosocial and genetic informa-
tion to construct the TRIAL database, which will improve 
the overall healthcare delivery for individuals with RTT. 
Using the functionality of the HealthTracker platform, the 
TRIAL database will provide all the necessary information 
to clinicians and researchers about different aspects of the 
disease and serve as a barometer for improving treatment 
pathways in individuals. This will allow algorithms to be 
developed alerting parent/carers to request unscheduled 
clinician appointments when symptoms deviate signifi-
cantly from one another thereby streamlining the patient 
care pathway. As the HealthTracker-based TRIAL data-
base is web based, with appropriate funding, it has the 
potential to be used globally, allowing for quicker devel-
opment of decision-support analytics and personalised 
care.
Rare disorders such as RTT have a limited patient 
population and it is therefore crucial for patients to be 
stratified using phenotype and biomarkers (such as those 
obtained through wearable sensor monitoring). Adap-
tive clinical trial design using Bayesian methodology 
has been suggested to augment the statistical power 
and decrease the number of patients required for a rare 
disease trial.72 In this view, the TRIAL database will serve 
for the recruitment of patients into clinical trials, as base-
line information would already be available so the clinical 
trial can be conducted with fewer patients and in a more 
cost-effective manner.
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Results stemming from this study will be disclosed unre-
servedly and the findings published in scientific journals 
and will also be presented in meetings and conferences 
for professionals, patients as well as carers and families. 
Reverse Rett UK will lead on wider dissemination of the 
applied research findings to engage policy-makers, key 
professional groups and service managers and parents/
carers of children with RTT.
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